2022-RA-579-ESGO A phase II study assessing safety and efficacy of cabozantinib for advanced or metastatic cervical carcinoma after platinum treatment failure (CABOCOL study)
2022-RA-579-ESGO A phase II study assessing safety and efficacy of cabozantinib for advanced or metastatic cervical carcinoma after platinum treatment failure (CABOCOL study)